Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 3 results.

- Journal article
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés, Javier Kim, Sung-Bae Chung, Wei-Pang Im, Seock-Ah Park, Yeon Hee Hegg, Roberto Kim, Min Hwan Tseng, Ling-Ming Petry, Vanessa Chung, Chi-Feng Iwata, Hiroji Hamilton, Erika Curigliano, Giuseppe Xu, Binghe Huang, Chiun-Sheng Kim, Jee Hyun Chiu, Joanne W Y Pedrini, Jose Luiz Lee, Caleb Liu, Yali Cathcart, Jillian Bako, Emarjola Verma, Sunil Hurvitz, Sara A DESTINY-Breast03 Trial Investigators Taylor, Donatienne[UCL] (2022) The New England journal of medicine — Vol. 386, no.12, p. 1143-1154 (2022)
- Speech
Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2021) 2021 ASCO Annual Meeting I —
- Speech
Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
Raghav, Kanwal Pratap Singh Yoshino, Takayuki Guimbaud, Rosine Chau, Ian Van den Eynde, Marc[UCL] Maurel, Joan Tie, Jeanne Kim, Tae Won Yeh, Kun-Huei Barrios, Daniel Kobayashi, Kojiro Bako, Emarjola Aregay, Mehreteab Meinhardt, Gerold Siena, Salvatore (2022) 2022 ASCO Gastrointestinal Cancers Symposium —